HERCULES CAPITAL - INVESTING IN TECH AND BIO BUSINESSES.

Hercules Capital $HTGC is a major business development company (BDC) that specializes in investing in technology and life sciences companies. Since its founding in 2003, the firm has invested more than $20 billion in over 650 companies, making it one of the major players in its sector. As a BDC, Hercules Capital is required to return at least 90% of its profits to investors in the form of dividends, avoiding income taxes, making it an attractive option for investors seeking a high dividend yield.

Benefits and structure of Hercules Capital

$HTGC focuses on smaller, high-risk investments, some of which may end in failure. Still, enough of these investments have proven successful to offset any losses. The company has a strong market position due to its diversification and equity positions in various sectors, particularly in the technology and life sciences sectors.

Dividend strategy

$HTGC is known for its generous dividend policy. It currently offers a quarterly dividend yielding 8.7%, which is well above average. Additionally, due to volatile cash flows that are closely tied to unpredictable technology stock prices, the company provides a supplemental dividend. This strategy not only stabilizes earnings, but also increases total return for investors. If the supplemental dividend remains unchanged, investors can achieve a total return of up to 10.3%, making Hercules Capital a very attractive investment.

$HTGC is a robust investment opportunity for those seeking a high dividend yield and with an appetite for the risk associated with the technology and life sciences sectors. The company offers not only a stable quarterly dividend, but also the potential for higher earnings through additional dividends.